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Abstract
Background: To eliminate blinding trachoma, the World Health Organization emphasizes implementing the SAFE strategy,
which includes annual mass drug administration (MDA) with azithromycin to the whole population of endemic districts.
Prevalence surveys to assess impact at the district level are recommended after at least 3 years of intervention. The decision
to stop MDA is based on a prevalence of trachomatous inflammation follicular (TF) among children aged 1–9 years below
5% at the sub-district level, as determined by an additional round of surveys limited within districts where TF prevalence is
below 10%. We conducted impact surveys powered to estimate prevalence simultaneously at the sub-district and district in
two zones of Amhara, Ethiopia to determine whether MDA could be stopped.
Methodology: Seventy-two separate population-based, sub-district surveys were conducted in 25 districts. In each survey
all residents from 10 randomly selected clusters were screened for clinical signs of trachoma. Data were weighted according
to selection probabilities and adjusted for correlation due to clustering.
Principal Findings: Overall, 89,735 residents were registered from 21,327 households of whom 72,452 people (80.7%) were
examined. The prevalence of TF in children aged 1–9 years was below 5% in six sub-districts and two districts. Sub-district
level prevalence of TF in children aged 1–9 years ranged from 0.9–76.9% and district-level from 0.9–67.0%. In only one
district was the prevalence of trichiasis below 0.1%.
Conclusions/Significance: The experience from these zones in Ethiopia demonstrates that impact assessments designed to
give a prevalence estimate of TF at sub-district level are possible, although the scale of the work was challenging. Given the
assessed district-level prevalence of TF, sub-district-level surveys would have been warranted in only five districts.
Interpretation was not as simple as stopping MDA in sub-districts below 5% given programmatic challenges of exempting
sub-districts from a highly regarded program and the proximity of hyper-endemic sub-districts.
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Introduction
Trachoma accounts for approximately 3% of global blindness and is
targeted for ‘‘elimination as a public health problem’’ by the year 2020
[1,2]. Trachoma is estimated to be endemic in 53 countries of which 35
have begun scaling-up or have fully implemented the recommended
SAFE strategy for reaching the elimination targets [3]. SAFE is the
acronym for an integrated package of interventions to treat, control,
and ultimately prevent new cases of blinding trachoma through surgery
(S), antibiotic distribution (A), facial cleanliness (F), and environmental
improvements (E) [4]. The ultimate intervention goal (UIG) for
trachoma control, defined by the World Health Organization (WHO)
as ‘‘elimination as a public health problem’’, is achieving a transmission
target: reducing trachomatous inflammation follicular in children aged
1–9 years (TF1–9) to less than 5%, and a morbidity target: less than 1
case of trachomatous trichiasis (TT) per 1,000 people [5].
WHO recommends annual mass drug administration (MDA)
with azithromycin or tetracycline ophthalmic ointment in areas
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where the district-level prevalence of TF1–9 is greater than 10%
[6]. A major challenge faced by national programs currently
implementing SAFE is determining when to stop MDA. Accord-
ing to guidelines issued after the 2nd global scientific meeting
(GSM) on trachoma in 2003, the impact of SAFE on the
prevalence of trachoma should be assessed after at least 3 years of
implementation and MDA stopped where the prevalence of TF1–9
is determined to be less than 5% in any community [6,7].
Realizing that estimating trachoma prevalence in every
community in sub-Saharan Africa places a heavy burden on
resource-constrained programs, the 3rd GSM on trachoma was
convened by WHO in July 2010 with the purpose of reviewing
and clarifying guidelines for the implementation of impact
assessment surveys, including the administrative level at which
impact must be measured to stop MDA. The new guidelines
suggest using the district as the evaluation unit (EU) on which to
estimate trachoma prevalence, followed by a decision to continue
SAFE or estimate trachoma prevalence through additional surveys
at the sub-district level to determine whether MDA could be
stopped. The new guidelines also suggest that ‘‘outcome surveys
can be used to pronounce achievement of UIG for TF, if the
sample size is powered to calculate estimates at the sub-district
level’’ [8].
The purpose of this study was to apply this latter statement from
the 3rd GSM in two different programmatic settings in the Amhara
region of Ethiopia by conducting trachoma outcome surveys at the
sub-district level to determine where MDA might be stopped. A
secondary aim of the study was to compare current estimates to
baseline prevalence in order to monitor impact of interventions.
Methods
Ethics Statement
The study protocols for surveys in both South Wollo and South
Gondar were reviewed and approved by the ethical review
committee of the Amhara Regional State Health Bureau.
Additionally, the study activities were approved by Emory
University Institutional Review Board under protocol 079-2006.
Due to the high rate of illiteracy, verbal informed consent was
obtained and recorded prior to data collection rather than written
information and a signed statement. Consent for trachoma
examination and household interview was obtained from heads
of households, individuals, and parents of minors according to the
principles of the declaration of Helsinki.
Study Site and Time Frame
Widespread implementation of the full SAFE strategy to all
endemic areas in Amhara was initiated in 2007, which included
outreach camps to provide surgery in addition to the existing static
service; annual MDA with antibiotics; promotion of facial
cleanliness and hygiene in schools and communities by health
extension workers; community-level promotion of latrine con-
struction and use through the health extension workers and
environmental health officers. Provision of improved water sources
was simultaneously supported by the development sector.
Previous data indicate that 6–12 months since the last round of
MDA is the ideal time to conduct impact surveys to assess
trachoma [9]. The outcome survey in South Wollo was conducted
in December 2010 in 13 woredas (districts) which had received a
third consecutive round of MDA in April 2010. The remaining
eight woredas in South Wollo had not yet received three rounds. In
South Gondar, training and field collection activities were
conducted in the rainy season from late June to early August
2011 covering all 12 woredas in the zone. All woredas in South
Gondar had received at least five rounds of MDA, the last round
of which took place in November 2010.
Sampling Methodology and Sample Size
The administrative levels of this area of Ethiopia and the
respective population at each tier are presented in Figure 1 with
the woreda being the district-level equivalent. From the 3rd GSM
report, a sub-district is defined as three or more villages with
combined total population of at least 30,000 people [8]. Since no
existing administrative level matched this description exactly, we
joined geographically adjacent health clusters in groups to create a
sub-district EU of approximately 50,000 cumulative population.
Gotts are the smallest administrative unit for which there is
population data available, which we used as our primary sampling
unit or cluster. For each EU surveyed, gotts were selected from a
line list arranged according to geographical distribution using a
standard methodology [10]. Gotts are broken down into smaller
administrative units called development teams (DT), which made ideal
segments on which to base a modified segmentation design for
equal probability sampling [10]. One DT was randomly selected
in each gott and all persons present or absent residing in all
households within the selected DT were registered and those
present examined. Absent households were registered as non-
consenting and were not replaced. Heads of household (or their
adult representative) were interviewed in consenting households.
Physical characteristics were recorded from direct observation.
To detect whether the prevalence of TF was 3% with 2%
precision, we calculated a sample size of 558 children aged 1–9
years per sub-district EU. This was based on a 5% level of
significance, design effect of 2, five persons per household with
children aged 1–9 years composing 30% of the total population.
To obtain the target sample size, population-based, cluster
random sampling was utilized for both surveys. We surveyed 10
clusters per sub-district, including 40 households per cluster,
which, based on our assumptions, would allow for an 8% non-
response rate in children.
Author Summary
Trachoma, the leading cause of preventable blindness, is
targeted for ‘‘elimination as a public health problem’’ by
the year 2020. National programs are implementing the
recommended strategy of surgery, antibiotics, facial
cleanliness, and environmental improvements (SAFE) to
meet this target. Many programs are currently facing the
decision of when to scale down interventions, particularly
mass drug administration (MDA) of azithromycin. We
implemented large population-based surveys in two
different zones of the Amhara National Regional State of
Ethiopia. Rather than conducting an impact assessment
first at the district level, followed by additional sub-district-
level surveys, we took a novel approach to measure the
prevalence of trachoma at sub-district level to be able to
make an immediate decision of whether to stop MDA.
Over 72,000 people in 714 communities in 72 sub-districts
were examined for clinical signs of trachoma. We identified
only six sub-districts that met criteria for being able to stop
MDA. Our work demonstrates that determining the
prevalence of trachoma at sub-district level is feasible
but requires significant resources. In this hyper-endemic
setting, sub-district-level surveys were not needed in the
majority of districts. Overall, the clinical data suggest some
decline in trachoma within these areas since the SAFE
strategy was implemented.
Prevalence of Trachoma at Sub-District Levels
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Training and Quality Control
Prior to the survey data collection, teams participated in a 7-
day, applied training and skills examination. Trachoma graders
were responsible for diagnosing the clinical signs of trachoma
using the simplified trachoma grading system [11]. Potential
graders were trained to classify signs of trachoma using digital
photographs, followed by examination with a standardized set of
photographs where agreement was calculated for all signs. Poor
performing participants were given additional instruction or
assigned other duties. Remaining participants practiced examina-
tion and diagnosis of trachoma for at least 2 days in volunteer
subjects of all ages resident in communities not selected for the
survey. Finally, the participants took a reliability exam to measure
their agreement with the ‘‘gold standard’’ grading of volunteer
subjects. The ‘‘gold standard’’ was the consensus grade of the
course trainers (ophthalmologist, trachoma program director, and
trachoma survey consultant) experienced with the simplified
trachoma grading system. Additionally, in South Wollo, digital
photos were taken of each eye included in the inter-observer exam
and reviewed to obtain consensus when trainers’ grades were
discordant. The agreement for all signs was generated, but selected
graders were those achieving greater than 84% agreement and a
Kappa $0.7 on grade TF.
Training for data recorders consisted of classroom instruction
and field practice, which included testing and refining the data
collection tools, applying the sampling strategy in the field, and
taking geographical coordinates of survey households. Persons
trained to serve as data recorders were also evaluated to assess
their ability to follow protocol, perform the interview, and record
responses correctly. The top performers were selected to work with
selected graders to form the final survey teams. A total of 21 teams
were deployed in South Wollo and 13 teams in South Gondar.
Data Collection, Management, and Analysis
Each head of household was interviewed to assess demographics
of the households and uptake of the SAFE strategy. All household
residents were examined for the presence or absence of all five
clinical signs of the simplified trachoma grading system in both
eyes using a 2.56 binocular loupe and adequate light [11].
Additionally, in 99 gotts of South Gondar, DNA specimens of the
tarsal conjunctivae of one randomly selected child aged 1–5 years
per household were collected using ocular swabs for detection of
infection with Chlamydia trachomatis by polymerase chain reaction
(PCR) (at the time of writing this article, results were not yet
available). The surveys also included non-trachoma indicators to
measure outcomes of integrated program interventions for malaria
in South Wollo and intestinal parasites in South Gondar. These
data have been presented elsewhere [12].
Data were collected by recorders on paper survey forms in
South Wollo zone. Forms were reviewed for completion by a team
leader prior to leaving the gott. Data in South Gondar were
collected electronically using Swift Insights, an Android (Google
Figure 1. Administrative levels and respective population structure of Amhara National Regional State, Ethiopia.
doi:10.1371/journal.pntd.0002732.g001
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Inc.) application, operated on tablet computers [13]. In South
Gondar, data recorders reviewed survey data after completing
each household prior to initiating the next house. In both zones,
supervisors met with each team at least once per two clusters
surveyed to provide needed materials and collect completed forms.
Data collected electronically were copied to an external micro SD
card and downloaded every 2–3 days by the team’s supervisor.
Paper-based survey data were double-entered inMicrosoft Access
by separate entry clerks, compared for discordance, and corrected
with the original hard-copy. Electronic data were downloaded at the
end of the survey separately for each team and converted from html
to csv format. Data were analyzed using STATA version 13
(STATA Corp., College Station, United States of America). The
inverse of the selection probabilities was calculated and used to
weight the data in the analysis. Additionally, the analysis accounted
for clustering at the gott, DT, and household levels by identifying the
complex survey design and generating a robust estimate of variance
[14]. Finite population corrections were provided for each stage of
sampling. Sub-district-level data were aggregated to generate
trachoma prevalence estimates at the district and zonal levels.
Current prevalence estimates were compared with a regional
baseline survey that provided zonal-level trachoma prevalence in
2006 [15] and, in South Gondar, from cross-sectional trachoma
surveys prior to pilot interventions. The statistical significance of
differences was assessed with a chi-square (X2) statistic accounting
for the survey designs.
Results
Teams successfully surveyed 714 of 720 communities from 72
EUs across the 25 woredas in the two zones. The six gotts not
surveyed were all in South Gondar and inaccessible during the
rainy season. Figure 2 shows the geographical distribution of the
714 communities in the two zones of Amhara National Regional
State, Ethiopia. A total of 89,735 residents were registered from
21,327 households of whom 72,452 (80.7%) were examined for
clinical signs of trachoma. A summary description of the sample
stratified by zone is shown in Table 1. Less than 2% of households
encountered in selected gotts refused to participate in the survey. A
higher proportion of residents were not available for examination
(absent from the house) in South Gondar than in South Wollo
(X2 = 1.73, p,0.001). The proportion of enumerated residents
examined was lowest among the adult male population (data not
shown). Among the target population, children aged 1–9 years,
95.8% and 94.9% of the enumerated children in South Wollo and
South Gondar were examined, respectively. The proportion of
these children with a clean face was 75.5% (95% confidence
interval (CI) 72.8–78.0%; range by woreda 54.0–95.9%). The mean
Figure 2. Surveyed communities in South Gondar and South Wollo zones of Amhara National Regional State, Ethiopia.
doi:10.1371/journal.pntd.0002732.g002
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number of children in the 1–9 year age group sampled in each EU
was 269.7 (standard deviation (SD) 50.6). The mean number of
people examined of all ages in each EU in South Wollo was 938.9
(SD 192.0). The prevalence estimates at the EU were based on a
mean sample size of 487.0 (SD 45.8) children 1–9 years of age and
1,073.7 (SD 106.8) total individuals examined per EU.
The sub-district-level and woreda-level prevalence of TF1–9,
classified as ,5%, 5–9%, and $10% is shown for both zones in
Figure 3. Overall, the prevalence of TF1–9 was below 5% in six
EUs and between 5% and 9% in an additional three EUs in South
Wollo (Table 2). According to the proposed WHO guidelines,
where the woreda-level TF1–9 prevalence is ,10%, MDA with
azithromycin may be stopped in EUs where TF1–9 prevalence is
less than 5%. In two woredas (Albuko and Mehal Saiynt; see Table
S1), at both the EU and woreda levels, the prevalence of TF1–9 was
below the 5% threshold and warranted stopping MDA in the
entire woreda. One additional EU in Tenta woreda also warranted
stopping MDA under the guidelines. The additional EU with TF1–
9 prevalence below 5% in Legambo woreda, while not identified in
the suggested way of district then sub-district surveys, meets the
UIG criteria. TF1–9 in 4 of 13 woredas was ,10% and would have
warranted further sub-district-level surveys. Neither at the woreda-
level nor in any single EU was the prevalence of TF1–9 below 5%
among children in South Gondar (see Table S2). Targeted MDA
at the sub-district level is recommended in three woredas (Tenta
and Mekidela in South Wollo, and Debre Tabor in South Gondar)
where TF1–9 prevalence was between 5% and 9%. For 20 of 25
woredas across the two zones, WHO guidelines suggest there was
no need for sub-district level assessment and MDA with
azithromycin should continue for at least an additional 3 years.
The prevalence of TF1–9 in the target age group for the
combined area in South Wollo zone was 26.4% (95% CI 23.7–
29.1%; range by woreda 0.9–67.0%; range by EU 0.9–76.9%) (see
Table S1). Prevalence of trachomatous inflammation intense (TI)
was 4.3% (95% CI 3.2–5.4%; range by woreda 0.7–22.0%; range
by EU 0.0–28.6%). Among all residents, the prevalence of TT was
1.3% (95% CI 1.1–1.5%; range by woreda 0.0–3.1%; range by EU
0.0–4.3%). In South Gondar (see Table S2), TF1–9 prevalence was
25.9% (95% CI 23.8–27.9%; range by woreda 8.6–44.9%; range by
EU 8.6–55.7%). Prevalence of TI was 7.0% (95% CI 6.2–7.8%;





gotts Houses Individuals Proportion male Adults$15 years Children 1–9 years
surveyed %** examined %** examined enumerated examined %** examined %**
Adjibar Saiynt 3 30 793 100 1,113 98.7 40.4 44.9 1,375 79.8 747 97.8
Albuko 2 20 440 89.2 1,504 69.7 46.6 51.9 894 69.2 429 79.7
Borena 3 30 895 98.7 3,360 90.6 46.3 48.6 1,829 94.7 971 99.7
Jamma 3 30 893 99.2 3,622 95.7 48.5 49.3 2,152 95.2 965 98.1
Kelala 3 30 719 92.7 2,415 77.8 44.4 48.8 1,342 75.9 711 88.0
Kutaber 2 20 477 96.4 1,798 87.6 46.8 49.7 1,036 85.0 451 94.6
Legambo 4 40 859 99.0 3,279 86.4 46.8 50.2 1,832 82.2 952 97.3
Legahida 2 20 421 100 1,725 96.6 49.3 50.3 962 95.3 493 98.4
Mehal Saiynt 2 20 506 100 1,942 87.4 45.6 48.7 1,021 82.6 622 98.1
Mekidela 3 30 991 99.8 3,819 98.6 47.4 47.4 2,285 99.1 1056 99.3
Tenta 3 30 751 99.7 2,349 74.0 43.1 49.9 1,368 69.7 657 92.9
Wogedi 3 30 792 99.9 2,714 86.5 43.3 46.5 1,472 83.0 841 96.3
Woreillu 3 30 726 99.3 2,903 89.7 45.3 48.0 1,640 86.3 813 98.2
South Wollo 36 360 9,263 98.2 33,800 87.0 45.8 48.6 19,208 84.9 9,708 95.8
Debre Tabor 1 10 368 100 1,109 69.7 36.7 44.4 515 55.8 519 96.1
Dera 4 39 1,325 99.9 4,350 78.0 41.6 48.2 1,903 65.8 2,128 96.4
East Estie 4 35 1,186 99.7 3,861 74.1 41.6 48.3 1,776 62.3 1,828 96.5
Ebinat 4 40 1,309 100 4,256 79.1 41.3 47.8 1,915 67.1 2,036 97.5
Farta 4 40 1,269 100 4,248 75.5 43.3 49.3 1,984 64.9 1,907 96.2
Fogera 3 30 985 98.6 3,415 77.2 43.3 49.1 1,607 69.4 1,399 92.9
Lay gayint 4 40 1,457 99.3 4,497 75.1 39.5 46.4 2,193 66.1 1,971 94.0
Libokem 3 30 1,020 99.3 3,289 74.3 41.0 48.3 1,529 65.8 1,482 92.9
Simada 4 40 1,407 99.5 4,135 73.7 38.8 46.1 2,011 65.5 1,800 91.0
Tach gayint 2 20 690 99.9 2,185 79.4 39.3 46.3 1,092 71.7 937 93.8
West Estie 2 20 689 100 2,180 77.6 42.4 47.7 1,033 67.6 1,011 96.0
Woreta town 1 10 359 100 1,127 75.5 39.3 46.7 509 62.5 543 96.8
South
Gondar
36 354 12,064 99.6 38,652 76.0 41.0 47.6 18,067 65.8 17,561 94.9
*Sub-district evaluation unit (EU).
** excluding 1.8% and 0.4% of households in South Wollo and South Gondar for which consent was not given.
doi:10.1371/journal.pntd.0002732.t001
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range by woreda 4.3–10.7%; range by EU 1.4–13.4%). The
prevalence of TT was 1.8% (95%CI 1.6–2.0%; range by woreda
1.0–3.5%; range by EU 0.6–4.2%) among the total examined
population.
In South Wollo, the prevalence of TF1–9 for the combined 13
woredas was higher than the baseline zonal estimate in 2006
(p = 0.013, Figure 4). The prevalence of TI in the current survey
was lower than the 10.6% estimate in 2006 (p= 0.053). Compared
Figure 3. Distribution of trachomatous inflammation folliclar (TF) among children aged 1–9 years in Amhara National Regional
State, Ethiopia. Data are stratified by woreda and evaluation unit.
doi:10.1371/journal.pntd.0002732.g003
Table 2. Summary of survey findings and recommended programmatic strategy for trachoma elimination in South Wollo and
South Gondar Zone, Ethiopia.
South Wollo South Gondar
EU* with TF,5% 6/36 0/36
EU* with 5%,TF,10% 3/36 1/36
woreda TF,5% 2/13 0/12
woreda 5%,TF,10% 2/13 1/12
woreda TT,0.1% 1/13 0/12
Recommended program
strategy`
Stop MDA in 6/36 EU with TF,5%. Conduct targeted MDA in
three EU with TF 5–9% (within 2 woredas). Continue district-
wide MDA in nine woredas for 3 more years. Enhance provision
of TT surgery in 12 woredas.
Conduct targeted MDA in one EU (within one
woreda) with TF 5–9%. Continue district-wide
MDA in 11 woredas for 3 more years. Enhance
provision of TT surgery in 12 woredas.
*Sub-district evaluation unit (EU).
`Interpretation of WHO guidelines.
doi:10.1371/journal.pntd.0002732.t002
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to estimates from two previous, cross-sectional, cluster randomized
surveys in South Gondar, the prevalence of TF1–9 decreased from
2003 (p,0.001) but did not change significantly from the estimate
in 2006 (p = 0.509). The current TI prevalence among children in
South Gondar was lower than previous estimates, 35.8% in 2003
(p,0.001) and 23.3% in 2006 (p,0.001).
Discussion
Recommendations of the 3rd GSM report suggested that, after
woreda-level surveys indicated a prevalence of TF1–9 below 10%,
sub-district-level estimates were required before making an
ultimate decision to cease MDA [8]. In each zone, we chose to
implement surveys in a single exercise to estimate the prevalence
of TF1–9 at the sub-district level in all districts eligible for outcome
surveys to avoid an additional round of surveys. We chose this
strategy for one main reason: to obtain a definite answer for all
areas in the two zones within a timeframe feasible for mobilizing
and implementing an annual MDA. Planning and implementing
impact surveys are vital but compete for financial and human
resources against the ongoing implementation of program
interventions, which require decisions for planning well ahead of
scheduled activities. For instance, submission of the application for
donated azithromycin and planning of its distribution occurs 8–20
months in advance of the intended distribution. Instead of having
a scenario where two surveys need to be completed prior to the
forecasting of drug needs, we felt a single survey, powered to
estimate the prevalence of both the sub-district and the district was
preferred. However, in this trachoma hyper-endemic region of
Ethiopia, conducting impact assessments first at the woreda level
would have provided necessary data for making the decision to
continue SAFE in 20 of the 25 woredas avoiding the need to survey
as many communities as was assessed.
According to the latest WHO guidelines, trachoma control
programs will eventually need to implement sub-district-level
surveys. The experience from implementing these large-scale
surveys in both zones, demonstrates that such surveys designed to
simultaneously measure disease prevalence at the sub-district and
district levels to evaluate impact of the SAFE strategy are indeed
feasible. However, the process was neither without challenge nor
the outcome without limitations. For instance, over 50 people were
required to implement each survey, including data recorders,
clinical examiners, drivers, supervisors, logisticians, and a coordi-
nator. During the training in both zones, only about half of the
clinical examiners met our pre-set criteria to participate in the
study even after several days of applied training. The final number
of survey teams is dependent on the number of examiners who can
accurately apply the trachoma grading system. If fewer examiners
meet the criteria, fewer teams can be deployed, which increases
the number of clusters each team must cover and the total number
of days in the field. In Amhara, the majority of gotts are accessible
only on foot or horseback. Once in the community, teams walked
long distances between houses within a selected DT to survey each
household and often slept overnight in the community to repeat
the process the next day. Accessibility in the field is further
constrained when surveys are conducted in the rainy season;
however, due to MDA forecasting needs and program implemen-
tation schedule, carrying out the survey in the rainy season was
unavoidable in South Gondar. In South Wollo, around 12,000
paper-based surveys were distributed to survey teams for data
collection. The printing, sorting, labeling, and distribution of these
forms took 18 person-days. Double data entry, comparison, and
correction took over 200 person-days and seven rental laptop
computers. Electronic data collection in South Gondar stream-
lined data management and saved substantial time [13]. Overall,
from planning to data analysis, each of these surveys took
approximately 3 months to complete, including 30 days of field
work. Our survey cost estimates are incomplete until the ocular
swab specimens are processed, but a generalizable median cost per
cluster of US$ 311 for conducting population-based prevalence
surveys of trachoma clinical signs was estimated previously [16].
Our decision to test this novel approach was also influenced by
an assumption that perhaps after 3–5 years of SAFE interventions,
TF1–9 would be reduced to less than 10%. Implementation of the
full SAFE strategy, including five consecutive, annual mass
azithromycin distribution campaigns did not result in a reduction
of TF1–9 prevalence below the UIG targets in any sub-district
within the trachoma hyper-endemic setting of South Gondar. The
Figure 4. Prevalence of active trachoma and clinical signs among children aged 1–9 years in Amhara National Regional State,
Ethiopia. Data are shown for the years 2003, 2006, and 2010–2011.
doi:10.1371/journal.pntd.0002732.g004
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impact on TF1–9 after 3 consecutive years of SAFE implementa-
tion was not as clear in South Wollo, where the overall prevalence
of TF1–9 was higher than the zonal-level prevalence estimated
prior to SAFE interventions. Yet, TF1–9 prevalence in a fraction of
the sub-districts assessed and two of 13 woredas were below the 5%
UIG. According to WHO guidelines these areas are eligible to stop
MDA for trachoma. Our sample of 9,708 children aged 1–9 years
across 360 communities in South Wollo provided much more
accurate and precise estimates than at baseline surveys. Indeed,
the baseline prevalence estimates for the entire zone of South
Wollo were derived from 484 children across 16 communities
[15]. The 12.6% TF1–9 estimate for South Wollo in 2006 was the
lowest for all 10 zones in the region and the only zone estimated
below 20% TF1–9 prevalence. In South Wollo, the observed
difference in TF1–9 prevalence compared to the baseline survey
was likely the results of an underestimate of the true TF1–9
prevalence at baseline due to chance. Four of the randomly
selected communities in 2006 were from woredas where the current
prevalence was lowest which might have contributed to a lower
prevalence estimate if TF1–9 prevalence was also less common at
baseline in these areas.
Additional prevalence data from South Gondar prior to 2006
suggest a decline of TF prevalence since the initiation of the
program (Figure 2), but a reduction in TF1–9 from 2006 to 2011
was not observed in the recent survey. Reduction in TF1–9 below
5% has been documented in other programs after SAFE
implementation, but in those settings the prevalence of TF1–9 at
baseline was lower than in Amhara [17,18]. TF1–9 prevalence in
South Sudan (also hyper-endemic for trachoma) was reduced to
below 5% after high community uptake of SAFE interventions but
this was observed only in one of four intervention sites [19].
One conclusion that could be made from the results is that a
lack of reduction in TF1–9 indicates that trachoma has not been
controlled and continued MDA is needed. Alternatively, trachoma
research studies from another region of Ethiopia have documented
slow resolution of clinical signs after MDA has successfully reduced
infection [20]. In one study, although a mean prevalence of 43.5%
TF was measured among children post 3 years of azithromycin
MDA, in a third of the participating communities, there was no
evidence of C. trachomatis infection [21]. A separate study from the
same area found infection prevalence of 2–3% in the context of
35% TF and/or TI prevalence after 3 years of either annual or
biannual MDA of azithromycin [22]. These studies suggest
difficulties in basing interpretations of impact and decisions to
stop antibiotic distribution on TF prevalence alone. A reduction in
the more severe active trachoma grade, TI, was observed in our
surveys compared to baseline data in both zones. A reduction in
TI was also documented in the first impact assessment conducted
in five woredas after 3 years of SAFE implementation in Amhara
[23]. An ordinal analysis of those data suggested a combination of
TF and TI might serve as a better impact indicator than TF alone,
which is also supported from a recent study in Tanzania [24,25].
According to current WHO guidelines, all woredas of South
Gondar warrant ongoing MDA with antibiotics [6]. After having
received five to seven rounds of MDA, the prevalence of C.
trachomatis infection is uncertain, but data from other studies in the
Amhara region raise the question of whether additional rounds
will provide further specific trachoma-related benefits [21–23]. In
hyper-endemic communities from a different region where region-
wide trachoma control interventions are not yet underway, a
rebound of C. trachomatis infection was observed 6–24 months after
no evidence of infection could be determined post-azithromycin
distribution [26]. In the Amhara setting where there is region-wide
intervention and fewer opportunities for exposure to re-infection,
infection data will provide crucial, additional evidence for MDA
decisions even though relative stopping thresholds based on
infection have only been suggested from mathematical models
[27]. We have not had the ability to process the collected
conjunctival DNA swabs to date due to constraints in the local
availability of reagents and national policies regarding exporting
clinical specimens.
Although these surveys are a landmark for trachoma control,
our results should be interpreted in the context of the following
limitations. The actual sample size achieved at the sub-district
level was lower than the estimated sample size desired. We
assumed a household size of five persons based on our prior work
in Ethiopia, when in fact the mean household size was smaller (i.e.,
four). The number of households in a DT was not 50 households
as projected, but varied greatly within a district. In South Wollo,
we found the DTs to be much smaller than anticipated. To correct
for this observation in South Gondar, multiple DTs were
randomly selected in each cluster. Yet, even in South Gondar
the actual sample size did not meet expectations. Selecting
different numbers of segments per cluster results in unequal
probability sampling which had to be adjusted for by weighting the
analysis according to the selection probabilities and doing so
decreases the precision of the estimates. If the actual point
prevalence findings for TF at the sub-district level had been near
the stopping threshold, then this may have been a reason for
concern; however, most of the sub-districts were well above 5% so
this should not bias decisions regarding MDA implementation.
Another limitation inherent with utilizing clinical signs of the
simplified trachoma grading system is that diagnosis is subjective
and has high variability between examiners of the same patient
[28]. While we took every means possible to select the most
capable, reliable graders, there will always be the chance of
systematic misclassification. Taking photographs of the everted lid
has been shown to provide an objective measure of findings in
some studies, but not in all settings and not at the scale of the
current study [29–31]. We used photographs only during the
standardization of the graders but capable cameras were not
deployed with any of the 34 survey teams. With the rapid
development in technology of devices which are used for electronic
data collection, it might be useful to explore improvements in the
capability of the smart device to capture photos of the tarsal
conjunctivae [32].
The decision to stop MDA is not straightforward. Strictly
following WHO guidelines, Amhara Regional Health Bureau
could cease MDA in six EUs in South Wollo. Programmatically,
planning and coordination of interventions is done by the district
and it is very difficult (politically and logistically) to exempt part of
the district while the other part continues to receive a perceived
benefit from the intervention. Scientifically, these six EUs are
within woredas geographically surrounded by areas where the
prevalence of TF warrants continued MDA (Figure 3). The spatial
distribution of trachoma and correlation of trachoma between sub-
districts may have implications on how stop-MDA decisions are
made. Additionally, identification of factors at the community and
geographical level associated with trachoma might assist in the
prediction of the presence or absence of trachoma post-interven-
tion and perhaps help minimize the amount of communities to be
surveyed [33].
The total cumulative output of SAFE activities through
December 2010 in Amhara, as reported by the Health Bureau
include: 192,922 persons operated to correct trichiasis, 50.9
million doses of azithromycin distributed, 3,428 kebeles with
ongoing trachoma-specific health education and over 1.8
million household latrines constructed (unpublished data). Facial
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cleanliness was specifically promoted in 1,324 schools. The
proportion of children with clean faces had not changed since
2006 [15], indicating either that face washing is not being adopted
or the measurement is confounded by other factors making this
indicator difficult to interpret [34]. Field reports of antibiotic
coverage ranged from 80–95% in each round, but these
administrative reports were not validated [35]. In addition to
clinical evaluation criteria on which to determine whether
trachoma is no longer a public health problem, the compliance
with the SAFE interventions, particularly hygiene and sanitation,
should be required. Low prevalence of clinical trachoma signs in
areas with low compliance of F and E interventions might be
interpreted differently than areas where household latrine
coverage, water access, and use for face washing is high. Such
indicators have been measured in these zones and show increases
in household sanitation and water access [14]. Additional
investigations are warranted to determine whether high coverage
of household-level access to water and sanitation supports
sustained reduction of trachoma prevalence after MDA has
stopped [36].
In conclusion, this study demonstrated that our methodology
was capable of providing estimates at both the district and sub-
district levels in a single survey, although minor adjustments would
be needed to consistently meet the required sample size at the sub-
district level. Implementing the survey at the sub-district level
irrespective of the district-level TF prevalence might identify sub-
districts which have met the control threshold for TF when the
district level prevalence remains above 10%, but this was rare.
Sub-district-level surveys would not have been warranted in most
of the districts assessed, even after 5 years of SAFE interventions.
This supports the current recommended approach of conducting
impact assessments at the district level first in similar trachoma
hyper-endemic settings. To obtain the sub-district-level estimates,
360 communities in a single zone had to be surveyed. While more
feasible than surveying every village as suggested by the previous
WHO recommendations, this number of clusters surveyed in each
zone was greater than that surveyed in some national-level
standardized surveys such as the multiple indicator cluster survey
and malaria indicator survey. Realizing the logistical challenges
posed by carrying out sub-district-level surveys and the difficulty of
interpreting TF prevalence to make program decisions, begs the
question: is there a better way to determine whether MDA could
be stopped?
Supporting Information
Checklist S1 STROBE checklist.
(DOC)
Table S1 Prevalence* of trachoma clinical signs by sub-
district evaluation unit (EU) and woreda in South Wollo,
Ethiopia, 2010.
(DOCX)
Table S2 Prevalence* of trachoma clinical signs by sub-




We gratefully acknowledge the residents of selected communities who gave
freely of their time to participate in the surveys. We are thankful for the
collaboration of the Lions-Carter Center Sight-First Initiative and the
Regional Health Bureau that enables the Amhara National Regional State
trachoma control program. We are grateful to the Zonal Level Health
Departments and Woreda Level Health Offices that facilitated movement
of survey teams. We thank The Carter Center logisticians and finance
officers for support during survey implementation. We appreciate the time,
effort, and attitude of all field teams, supervisors, drivers, trainers, and
coordinators of the survey. Finally, we appreciate those who entered over
9,000 paper survey forms from South Wollo and for Georgia Institute of
Technology student volunteers, Joy Buolamwini and Andrew Panfel who
have considerably improved the survey process through their ingenious
electronic data collection and management software.
Author Contributions
Conceived and designed the experiments: JDK EAC JMN TGebre ZT PO
JU GH PME. Performed the experiments: JDK TT EACMZMD FA AM
AK BM MA DG AW TE FAA NES MRAK AWM TGebreg GH.
Analyzed the data: JDK. Contributed reagents/materials/analysis tools:
NES TE. Wrote the paper: JDK. Contributed to the editing of the
manuscript: JDK TT EAC MZ MD FA AM AK BM MA DG AW TE
FAA NES MRAK AWM TGebreg ZT PO JU GH PME.
References
1. World Health Assembly (1998) WHA resolution 51.11 Global elimination of
blinding trachoma. Geneva: World Health Organization.
2. WHO (2012) Global data on visual impairments 2010. Geneva: World Health
Organization.
3. WHO (2012) Global WHO alliance for the elimination of blinding trachoma by
2020. Wkly Epidemiol Rec 87: 161–168.
4. WHO (1997) Future approaches to trachoma control. Geneva: World Health
Organization.
5. Resnikoff S, Huguet P, Mariotti SP (2007) Certification of the elimination of
blinding trachoma by the World Health Organization. Rev Int Trach Pathol
Ocul Trop Subtrop Sante Publique 84: 59–68.
6. WHO (2006) Trachoma control: a guide for program managers. Geneva: World
Health Organization.
7. WHO (2004) Report from the 2nd global scientific meeting on trachoma.
Geneva, Switzerland 25–27 August 2003. Geneva: World Health Organization.
8. WHO (2011) Report from the 3rd global scientific meeting on trachoma.
Baltimore, Maryland 19–20 July 2010. Geneva: World Health Organization.
9. Ngondi J, Gebre T, Shargie E, Adamu L, Teferi T, et al. (2010) Estimation of
effects of community intervention with antibiotics, facial cleanliness, and
environmental improvement (A,F,E) in five districts of Ethiopia hyperendemic
for trachoma. Br J Ophthalmol 94: 278–281.
10. UNICEF (2006) Multiple indictor cluster survey manual 2005. New York: The
United Nations Children’s Fund.
11. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR (1987) A simple
system for the assessment of trachoma and its complications. Bull World Health
Organ 65: 477–483.
12. King JD, Endeshaw T, Escher E, Alemtaye G, Melaku S, et al. (2013) Intestinal
parasite prevalence in an area of Ethiopia after implementing the SAFE strategy,
enhanced outreach services, and health extension program. PLoS Negl Trop Dis
7: e2223.
13. King JD, Buolamwini J, Cromwell EA, Panfel A, Teferi T, et al. (2013) A novel
electronic data collection system for large-scale surveys of neglected tropical
diseases. PLoS One 8: e74570.
14. Kolenikov S (2010) Resampling variance estimation for complex survey data.
Stata J 10: 165–199.
15. Emerson PM, Ngondi J, Biru E, Graves PM, Ejigsemahu Y, et al. (2008)
Integrating an NTD with one of ‘‘The big three’’: combined malaria and
trachoma survey in Amhara Region of Ethiopia. PLoS Negl Trop Dis 2: e197.
16. Chen C, Cromwell EA, King JD, Mosher A, Harding-Esch EM, et al. (2011)
Incremental cost of conducting population-based prevalence surveys for a
neglected tropical disease: the example of trachoma in 8 national programs.
PLoS Negl Trop Dis 5: e979.
17. Solomon AW, Harding-Esch E, Alexander ND, Aquirre A, Holland MJ, et al.
(2008) Two doses of azithromycin to eliminate trachoma in a Tanzanian
community. N Engl J Med 358: 1870–1871.
18. Yayemain D, King JD, Debrah O, Emerson PM, Aboe A, et al. (2009)
Achieving trachoma control in Ghana after implementing the SAFE strategy.
Trans R Soc Trop Med Hyg 103: 993–1000.
19. Ngondi J, Onsarigo A, Matthews F, Reacher M, Brayne C, et al. (2006) Effect of
3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental
change) strategy for trachoma control in southern Sudan: a cross-sectional study.
Lancet 368: 589–595.
Prevalence of Trachoma at Sub-District Levels
PLOS Neglected Tropical Diseases | www.plosntds.org 9 March 2014 | Volume 8 | Issue 3 | e2732
20. Keenan JD, Lakew T, Alemyehu W, Melese M, House JI, et al. (2011) Slow
resolution of clinically active trachoma following successful mass antibiotic
treatments. Arch Ophthalmol 129: 512–513.
21. Keenan JD, Ayele B, Gebre T, Moncada J, Stoller NE, et al. (2012) Ribosomal
RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass
azithromycin distributions in communities with highly prevalence trachoma.
Clin Infect Dis 54: 253–256.
22. Gebre T, Ayele B, Zerihun M, Gene A, Stoller NE, et al. (2012) Comparison of
annual versus twice-yearly mass azithromycin treatment for hyperendemic
trachoma in Ethiopia: a cluster-randomised trial. Lancet 379: 143–151.
23. Ngondi J, Gebre T, Shargie E, Adamu L, Ejigsemahu Y, et al. (2008) Evaluation
of three years of the SAFE strategy (surgery, antibiotics, facial cleanliness and
environmental improvement) for trachoma control in the five districts of
Ethiopia hyperendemic for trachoma. Trans R Soc Trop Med Hyg 103: 1001–
1010.
24. Ngondi J, Matthews F, Reacher M, Onsarigo A, Matende I, et al. (2007)
Prevalence of risk factors and severity of active trachoma in Southern Sudan: an
ordinal analysis. Am J Trop Med Hyg 77: 126–132.
25. Munoz B, Stare D, Mkocha H, Gaydos C, Quinn T, et al. (2011) Can clinical
signs of trachoma be used after multiple rounds of mass antibiotic treatment to
indicate infection? Invest Ophthalmol Vis Sci 52: 8806–8810.
26. Lakew T, House J, Hong KC, Yi E, Alemayehu W, et al. (2009) Reduction and
return of infectious trachoma in severely affected communities in Ethiopia. PLoS
Negl Trop Dis 3: e394.
27. Ray KJ, Lietman TM, Porco TC, Keenan JD, Bailey RL, et al. (2009) When can
antibiotic treatments for trachoma be discontinued? Graduating communities in
three African countries. PLoS Negl Trop Dis 3: e458.
28. Miller K, Schmidt G, Melese M, Alemayehu W, Yi E, et al. (2004) How reliable
is the clinical exam in detecting ocular chlamydial infection? Ophthal Epi 11:
255–262.
29. West SK, Taylor HR (1990) Reliability of photographs for grading trachoma in
field studies. Br J Ophthalmol 74: 12–13.
30. Solomon AW, Bowman RJC, Yorston D, Massae PA, Safari S, et al. (2006)
Operational evaluation of the use of photographs for grading active trachoma.
Am J Trop Med Hyg 74: 505–508.
31. Roper KG, Taylor HR (2009) Comparison of clinical and photographic
assessment of trachoma. Br J Ophthalmol 93: 811–814.
32. Bhosai SJ, Amza A, Beido N, Bailey RL, Keenan JD, et al. (2012) Application of
smartphone cameras for detecting clinically active trachoma. Br J Ophthalmol
96: 1350–1351.
33. Clements ACA, Kur LW, Gatpan G, Ngondi JN, Emerson PM, et al. (2010)
Targeting trachoma control through risk mapping: the example of Southern
Sudan. PLoS Negl Trop Dis 4: e799.
34. King JD, Ngondi J, Kasten J, Diallo MO, Zhu H, et al. (2011) Randomised trial
of face-washing to develop a standard definition of a clean face for monitoring
trachoma control programmes. Trans R Soc Trop Med Hyg 105: 7–16.
35. Cromwell EA, Ngondi J, McFarland D, King JD, Emerson PM (2012) Methods
for estimating population coverage of mass distribution programmes: a review of
practices in relation to trachoma control. Trans R Soc Trop Med Hyg 106: 588–
595.
36. Haile M, Tadesse Z, Gebreselassie S, Ayele B, Gebre T, et al. (2013) The
association between latrine use and trachoma: a secondary cohort analysis from
a randomized clinical trial. Am J Trop Med Hyg 89: 717–720.
Prevalence of Trachoma at Sub-District Levels
PLOS Neglected Tropical Diseases | www.plosntds.org 10 March 2014 | Volume 8 | Issue 3 | e2732
